MIRM - Mirum Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.23
-1.35 (-6.26%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close21.58
Open21.58
Bid20.06 x 900
Ask21.34 x 1000
Day's Range19.83 - 22.23
52 Week Range6.51 - 28.31
Volume236,648
Avg. Volume350,546
Market Cap456.98M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-9.33
Earnings DateNov 05, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.40
  • PR Newswire

    Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund

    Frazier Healthcare Partners announced today the closing of Frazier Life Sciences X, L.P., exceeding its target and closing on more than $617 million in capital commitments in an oversubscribed fundraise. Investing in life sciences has been a core strategy since the firm's inception 29 years ago, and Frazier Life Sciences X marks the third dedicated Life Sciences fund, bringing the firm's total committed capital raised since inception to nearly $4.8 billion.

  • Business Wire

    Mirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer

    Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the promotion of Ian Clements to Chief Financial Officer. Dr. Clements joined Mirum in March 2019 and most recently served as Senior Vice President, Finance and Communications.

  • Business Wire

    Mirum Pharmaceuticals Announces Pricing of Public Offering

    Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the pricing of its public offering of 2,400,000 shares of its common stock at a price to the public of $20.00 per share. The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $48.0 million.

  • Is Mirum Pharmaceuticals, Inc. (MIRM) A Good Stock To Buy?
    Insider Monkey

    Is Mirum Pharmaceuticals, Inc. (MIRM) A Good Stock To Buy?

    Is Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]

  • Benzinga

    The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...

  • Business Wire

    Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat

    Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the successful completion of its clinical pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for maralixibat for the treatment of pruritus associated with Alagille syndrome. In addition, the company had a chemistry, manufacturing and controls (CMC) meeting with the FDA. The purpose of the meetings was to discuss and confirm the clinical, non-clinical and CMC requirements for the company’s proposed NDA submission. The company also today announced that Rare Pediatric Disease Designation has been granted for maralixibat for Alagille syndrome, and thus may qualify for the receipt of a priority review voucher if the NDA is approved by the FDA. Maralixibat was recently granted Breakthrough Therapy Designation by the FDA for Alagille syndrome.

  • Business Wire

    Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast

    Mirum Pharmaceuticals today announced it will provide a regulatory update in a webcast and conference call.

  • Business Wire

    Mirum Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference

    Mirum Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will participate at the Evercore ISI 2nd Annual HealthCONx Conference.

  • Business Wire

    Mirum Pharmaceuticals Presents Data Demonstrating Long-term Durability of Treatment Effect of Maralixibat in Children With Cholestatic Liver Diseases

    Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that results from the long-term extension of the Phase 2b ICONIC study demonstrate the durability of treatment effect and disease-modifying potential of maralixibat in children with Alagille syndrome (ALGS). The data will be presented on Monday in a late breaking oral presentation at the annual meeting of the American Association of the Study of Liver Diseases (the Liver Meeting®) in Boston.

  • Business Wire

    Mirum Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

    Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome Granted

  • Business Wire

    Mirum Pharmaceuticals Announces Appointment of Ed Tucker as Chief Medical Officer

    Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the appointment of Ed Tucker, M.D. as its chief medical officer. Dr. Tucker has over 20 years of academic, biotechnology and pharmaceutical drug development experience, from early clinical phase through post-commercialization.

  • Business Wire

    Mirum Pharmaceuticals Announces Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome

    Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for maralixibat for the treatment of pruritus associated with Alagille syndrome (ALGS) in patients 1 year of age and older.

  • Business Wire

    Durability of Treatment Effect of Mirum Pharmaceuticals’ Maralixibat for Children With Alagille Syndrome Featured in Late Breaking Session at the Liver Meeting 2019

    Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that data on its program for the treatment of children with maralixibat will be featured in the late breaking oral presentation session during the American Association for the Study of Liver Diseases Annual Meeting (The Liver Meeting), November 8-12, 2019, in Boston. “We are very pleased to be presenting the long-term treatment effect of maralixibat in Alagille syndrome patients from the ICONIC study, highlighting the potential impact of maralixibat on this terrible disease,” said Chris Peetz, president and chief executive officer of Mirum.

  • Business Wire

    Mirum Pharmaceuticals to Present New Data at The Liver Meeting 2019

    Mirum Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that multiple maralixibat abstracts will be presented at The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Disease , taking place November 8-12, 2019 in Boston, ...

  • Benzinga

    Mirum Pharma's Lead Asset Has $450M Sales Opportunity, Raymond James Says In Bullish Initiation

    Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) recently went public, offering 5 million shares at $15 each. With the IPO quiet period expiring, analysts are kicking off coverage of the stock.   The Analyst ...

  • Mirum Pharmaceuticals Announces Pricing of Initial Public Offering
    PR Newswire

    Mirum Pharmaceuticals Announces Pricing of Initial Public Offering

    FOSTER CITY, Calif., July 17, 2019 /PRNewswire/ -- Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share. The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $75,000,000. The shares are expected to begin trading on the Nasdaq Global Market on July 18, 2019 under the symbol "MIRM".

  • Benzinga

    IPO Outlook For The Week: Biotechs, Financial Advisers, Medical Services And The Twitch Of China

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Douyu International Holdings Ltd (DOYU) will issue nearly 67.4 million ...

  • Benzinga

    Mirum Pharmaceuticals IPO: What You Need To Know

    Foster City, California-based Mirum Pharmaceuticals is planning a 5-million share IPO at an estimated price range of $14-$16, according to an amended prospectus filed with the SEC July 8. The company said in the filing that certain of its shareholders, directors and their affiliated entities, have expressed interest in purchasing an aggregate of up to about $35 million worth of shares. Mirum is a biopharma company, which focuses on developing novel therapies for debilitating liver diseases.